Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buxó

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Journal of Neurology|March 2, 2025
Late-onset vestibulocerebellar ataxia: clinical and genetic studies in a long follow-up series of 50 patientsDavid Genís, Berta Alemany, David Pellerin, et al.
Aging|May 12, 2019
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patientsElisabet Cuyàs, Salvador Fernández-Arroyo, Maria Buxó, et al.
Journal of Clinical Medicine|December 15, 2019
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast CancerEugeni Lopez-Bonet, Maria Buxó, Elisabet Cuyàs, et al.
Frontiers in Oncology|April 16, 2019
The <i>C</i> Allele of <i>ATM</i> rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant MetforminElisabet Cuyàs, Maria Buxó, Maria José Ferri Iglesias, et al.
Oncotarget|November 28, 2018
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN studyBegoña Martin-Castillo, Sonia Pernas, Joan Dorca, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Journal of Neurology|March 2, 2025
Late-onset vestibulocerebellar ataxia: clinical and genetic studies in a long follow-up series of 50 patientsDavid Genís, Berta Alemany, David Pellerin, et al.
Aging|May 12, 2019
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patientsElisabet Cuyàs, Salvador Fernández-Arroyo, Maria Buxó, et al.
Journal of Clinical Medicine|December 15, 2019
Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast CancerEugeni Lopez-Bonet, Maria Buxó, Elisabet Cuyàs, et al.
Frontiers in Oncology|April 16, 2019
The <i>C</i> Allele of <i>ATM</i> rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant MetforminElisabet Cuyàs, Maria Buxó, Maria José Ferri Iglesias, et al.
Oncotarget|November 28, 2018
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN studyBegoña Martin-Castillo, Sonia Pernas, Joan Dorca, et al.
Pageof 7